PT  - JOURNAL ARTICLE
AU  - Yin Shen
AU  - Ling-Ling Chen
AU  - Junxiang Gao
TI  - CharPlant: A &lt;em&gt;De Novo&lt;/em&gt; Open Chromatin Region (OCR) Prediction Tool for Plant Genomes
AID  - 10.1101/2020.10.27.358218
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.10.27.358218
4099  - http://biorxiv.org/content/early/2020/10/28/2020.10.27.358218.short
4100  - http://biorxiv.org/content/early/2020/10/28/2020.10.27.358218.full
AB  - Chromatin accessibility is a highly informative structural feature for understanding gene transcription regulation because it indicates the degree to which nuclear macromolecules such as proteins and RNA can access chromosomal DNA. Studies show that chromatin accessibility is highly dynamic during stress response, stimulus response, and developmental transition. Moreover, physical access to chromosomal DNA in eukaryotes is highly cell-specific. Therefore, current technologies such as DNase-seq, ATAC-seq, and FAIRE-seq reveal only a portion of the open chromatin regions (OCRs) present in a given species. Thus, the genome-wide distribution of OCRs remains unknown. In this study, we developed a bioinformatics tool called CharPlant for the de novo prediction of chromatin accessible regions in plant genomes. To develop this tool, we constructed a three-layer convolutional neural network (CNN) and subsequently trained the CNN using DNase-seq and ATAC-seq datasets of four plant species. The model simultaneously learns the sequence motifs and regulatory logics, which are jointly used to determine DNA accessibility. All of these steps are integrated into CharPlant, which can be run using a simple command line. The results of data analysis using CharPlant in this study demonstrate its prediction power and computational efficiency. To our knowledge, CharPlant is the first de novo prediction tool that can identify potential OCRs in the whole genome. The source code of CharPlant and supporting files are freely downloadable from https://github.com/Yin-Shen/CharPlant.Competing Interest StatementThe authors have declared no competing interest.